Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications
Open Access
- 23 January 2018
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (4) , 404-406
Abstract
Publication of interim results of randomized trials can be consequential, potentially undermining trial integrity by unblinding or encouraging dropouts and crossovers,1 introducing uncertainty because results based on fewer outcomes are less precise, or overstating true treatment effects as demonstrated primarily in trials terminated early2,3 but also in ongoing trials.4 Nevertheless, because interim results are new and often promising, they may generate substantial interest, which can be misleading if results change. We describe the characteristics of interim publications from ongoing randomized trials and compare their consistency and prominence with those of final publications.Keywords
This publication has 6 references indexed in Scilit:
- Publishing interim results of randomised clinical trials in peer-reviewed journalsClinical Trials, 2016
- Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent researchClinical Trials, 2016
- Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?Lung Cancer, 2014
- High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trialHaematologica, 2012
- Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression AnalysisJAMA, 2010
- High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyHaematologica, 2010